伊立替康联合奈达铂治疗复发耐药晚期上皮卵巢癌的疗效和毒副作用

Efficacy and toxicity of irinotecan combined with nedaplatin for recurrent and refractory advanced epithelial ovarian carcinoma

目的探讨伊立替康(IRI)联合奈达铂(NDP)治疗复发耐药晚期上皮卵巢癌的临床疗效和毒副作用。方法将104例复发耐药晚期上皮卵巢癌患者随机分为两组,观察组(52例)采用IRI+NDP方案化疗,对照组(52例)单用IRI化疗。比较分析两组的总有效率(ORR)、疾病控制率(DCR)、Karnofsky评分与毒副作用。结果观察组的ORR和DCR分别为53.8%和75.0%,显著高于对照组19.2%和55.8%(P<0.05);化疗后,两组Karnofsky评分均较化疗前显著提高(P<0.05),而观察组Karnofsky评分的升高程度明显高于对照组(P<0.05);观察组血小板减少、粒细胞减少的并发症发生率高于对照组(P<0.05)。结论 IRI+NDP方案可提高化疗的有效率和疾病控制率,且具有相对良好的安全性及耐受性,可作为复发耐药晚期上皮卵巢癌的理想治疗方案。

Objective To explore clinical effect and toxicity of irinotecan（IRI） combined with nedaplatin（NDP） for treatment of recurrent and refractory advanced epithelial ovarian carcinoma.Methods 104 cases of recurrent and refractory advanced epithelial ovarian carcinoma were randomly divided into two groups.The observation group（n=52） was given IRI＋NDP,and control group（N=52） was given IRI alone,respectively.The overall response rate（ORR）,disease control rate（DCR）,Karnofsky score and main toxicities were observed.Results The ORR and DCR in observation group（53.8% and 75.0%,respectively） were significantly higher than those in control group（19.2% and 55.8%,respectively）（P0.05）.After chemotherapy treatment,Karnofsky scores were significantly higher than those before treatment,and Karnofsky scores in observation group were increased more remarkably than those in control group（P0.05）.The toxicities of thrombocytopenia and granulocytopenia in observation group were significantly higher than those in control group（P0.05）.Conclusion IRI＋NDP can contribute to improve ORR and DCR,and has a relative good safety and tolerance,so it can be served as an ideal therapeutic schedule for recurrent and refractory advanced epithelial ovarian carcinoma.